Cathepsin S

Therapy area
Autoimmune diseases e.g. rheumatoid arthritis, multiple sclerosis and neuropathic pain.

 
Phase
Preclinical optimization phase.
Competitive edge
Cathepsin S inhibitors have the potential for improved efficacy, fewer side-effects and better cost-effectiveness than current autoimmune therapies.

 Project data

  • Highly potent compounds with exellent selectivity and pharmacokinetic properties identified
  • Selected Cathepsin S inhibitor compounds are being evaluated in preclinical models of RA and neuropathic pain


Last Modified: 12/05/2009